Clinical Trials
Learn about available clinical trials
-
5 de april de 2021PamplonaIn recruitment
IO-001_08 Clinical trial of EOS100850 as a single agent or in combination with pembrolizumab or chemotherapy in participants with advanced cancers.
The aim of this trial is to evaluate how your body tolerates the drug EOS100850 and what effects it has on the tumor. In addition, it will investigate what happens to EOS100850 in your body, how you get rid of it and what effects EOS100850 has on your body. The effects of EOS100850 will be investigated by blood samples and tumor biopsies, as well as by measuring changes in tumor size. -
5 de april de 2021PamplonaIn recruitment
-
29 de march de 2021PamplonaIn recruitment
ADP-0055-001 Clinical trial of ADP-A2M4CD8 in HLA-A2 patients with MAGE-A4-expressing tumors.
The objective is to evaluate the safety and efficacy of ADP-A2M4CD8 in HLA-A2 patients with MAGE-A4-expressing tumors. -
22 de march de 2021PamplonaIn recruitment
BNT122-01 Clinical trial of RO7198457 in patients with resected stage II and stage III colorectal cancer with circulating tumor DNA positivity after tumor resection.
The objective of this study is to learn about the effects of an experimental treatment called RO7198457. RO7198457 is considered "experimental" because it has not yet received approval from the Spanish Agency of Medicines and Health Products for the treatment of any disease. -
22 de march de 2021MadridIn recruitment
D9950C00001 Trial of AZD8701 in combination with durvalumab in participants with advanced solid tumors.
We are doing this study to find out whether the drug called AZD8701 will be safe for the treatment of different types of cancers when given alone or when given with the drug durvalumab. -
22 de march de 2021MadridIn recruitment
MK3475-B21 Clinical trial of pembrolizumab versus placebo in combination with adjuvant chemotherapy for the treatment of newly diagnosed high-risk endometrial cancer.
This trial is being conducted to evaluate pembrolizumab versus placebo in combination with carboplatin and paclitaxel with or without radiotherapy and: -Evaluate safety. -To check if it is effective. -To test whether participants receiving pembrolizumab live longer than those receiving placebo. -
22 de march de 2021PamplonaIn recruitment
D910MC00001 Trial of durvalumab in patients with stage II-III non-small cell lung cancer with minimal residual disease after surgery and treatment with curative intent.
The aim of this trial is to identify those patients who have small amounts of tumor DNA in the blood after treatment (surgery ± additional treatment [such as chemotherapy] before or after surgery), but no evidence of cancer on imaging studies. -
12 de march de 2021PamplonaIn recruitment
M19-753 Clinical trial of navitoclax in monotherapy and in combination with ruxolitinib in patients with myeloproliferative neoplasms.
The purpose of this study is to understand the effects that navitoclax may have on your heart, specifically, on electrocardiographic measurements in patients with myelofibrosis or chronic myelomonocytic leukemia in the U.S. and Europe. -
12 de march de 2021PamplonaIn recruitment
CA224-073 Trial of relatlimab in combination with nivolumab in patients with advanced hepatocellular carcinoma naïve to immuno-oncological treatments, who have progressed to tyrosine kinase inhibitors.
The objective of this study is to study the safety and efficacy of relatlimab combined with nivolumab versus nivolumab alone in patients with primary liver cancer and also to study whether patients who have a higher amount of a protein called lymphocyte activation gene 3 (LAG-3) in their tumor tissue would respond better to this combination regimen compared to patients who have a lower amount of this protein in their tumor tissue. -
12 de march de 2021PamplonaIn recruitment
M19-025 Multiple myeloma and acute myeloid leukemia: first human study of an MCL-1 inhibitor (incorporates version 3.0 protocol)
The purpose of the study is to test whether ABBV-467, the study drug, is safe, to identify safe doses of ABBV-467, to measure the amount of ABBV-467 present in the blood at various times (these tests are called ¿pharmacokinetics¿ or ¿FC¿), and to determine whether treatment with ABBV-467 has an effect on various cancers. This study is being conducted in patients with multiple myeloma (MM) or acute myeloid leukemia (AML) that has relapsed or is refractory (meaning that...